Back to School: How biopharma can reboot drug development. Access exclusive analysis here

SmithKline returns rights to Coulter

SmithKline Beecham (LSE:SB; SBH) returned development and commercialization rights to CLTR's Bexxar cancer therapy outside the U.S. As a result, CLTR will be eligible for less than the $76 million in milestones

Read the full 326 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE